HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alita A Miller Selected Research

Lactams

4/2024Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).
12/2023Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
11/2023Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii.
1/2023Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.
1/2022In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
1/2022Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.
1/2021In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.
1/2021Ceftazidime-Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime-ETX1317 Susceptibility.
11/2020Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
1/2020In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alita A Miller Research Topics

Disease

15Infections
04/2024 - 08/2008
3Acinetobacter Infections
01/2023 - 01/2021
1Coinfection
04/2024
1Bacterial Pneumonia
12/2023
1Melioidosis
01/2021
1Urinary Tract Infections (Urinary Tract Infection)
01/2021
1Gonorrhea
12/2020
1Gram-Negative Bacterial Infections
11/2020
1Communicable Diseases (Infectious Diseases)
09/2014
1Cross Infection (Nosocomial Infection)
06/2013
1Staphylococcal Infections
01/2013

Drug/Important Bio-Agent (IBA)

10sulbactam-durlobactamIBA
04/2024 - 01/2020
10LactamsIBA
04/2024 - 01/2020
9Anti-Bacterial Agents (Antibiotics)IBA
04/2024 - 08/2008
7Carbapenems (Carbapenem Antibiotics)IBA
04/2024 - 11/2020
4durlobactamIBA
12/2023 - 01/2021
3SulbactamFDA LinkGeneric
12/2023 - 01/2021
2Colistin (Coly-Mycin)FDA Link
04/2024 - 04/2024
2Cefpodoxime Proxetil (Vantin)FDA LinkGeneric
01/2021 - 11/2020
2ProdrugsIBA
01/2021 - 11/2020
2VaccinesIBA
01/2013 - 11/2012
1Imipenem Drug Combination Cilastatin (Primaxin)FDA Link
04/2024
1ImipenemFDA Link
04/2024
1Penicillin-Binding Proteins (Penicillin-Binding Protein)IBA
01/2023
1zoliflodacinIBA
12/2020
1EstersIBA
11/2020
1Polymyxins (Polymyxin)IBA
06/2013

Therapy/Procedure

4Therapeutics
04/2024 - 11/2020
1Mechanical Ventilators (Ventilator)
12/2023